Abstract
Purpose
Multidrug resistance (MDR) remains a major obstacle to successful chemotherapeutic treatment of cancer. Several chemotherapeutic and radiopharmaceutical agents are substrates of the pumps encoded by the MDR genes, and therefore, their accumulation is prevented. We evaluated in vivo whether [99mTc]tetrofosmin (99mTc-TF) uptake is influenced by the MDR profile of gliomas.
Procedures
Eighteen patients with histologically confirmed glioma were included in the study. Brain single-photon emission computed tomography by 99mTc-TF was performed within a week prior to surgical excision, and the expression of MRP5 was assessed by immunohistochemistry. Radiotracer accumulation was assessed by a semiquantitative method, calculating the lesion-to-normal uptake ratio.
Results
Using Spearman's ρ analysis, we found no correlation between tracer uptake expressed as lesion-to-normal and MRP5 expression. There was a significant correlation between glioma aggressiveness as assessed by Ki-67/MIB-1 and MRP5 expression.
Conclusion
The present data suggest that 99mTc-TF uptake is not influenced by glioma's MDR phenotype. Thus, 99mTc-TF constitutes a suitable radiotracer for imaging gliomas.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Spiegl-Kreinecker S, Buchroithner J, Elbling L et al (2002) Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrugresistance protein 1 in human brain tumor cells and astrocytes. J Neurooncol 57:27–36
Mousseau M, Schaerer R, Pasquier B et al (1993) A study of the expression of four chemoresistance-related genes in human primary and metastatic brain tumours. Eur J Cancer 29A:753–759
Abe T, Mori T, Wakabayashi Y et al (1998) Expression of multidrug resistance protein gene in patients with glioma after chemotherapy. J Neurooncol 40L:11–18
Nies AT, Jedlitschky G, König J et al (2004) Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience 129:349–360
Le Jeune N, Perek N, Denoyer D, Dubois F (2005) Study of monoglutathionyl conjugates TC-99M-sestamibi and TC-99M-tetrofosmin transport mediated by the multidrug resistance-associated protein isoform 1 in glioma cells. Cancer Biother Radiopharm 20:249–259
Le Jeune N, Perek N, Denoyer D, Dubois F (2004) Influence of glutathione depletion on plasma membrane cholesterol esterification and on Tc-99m-sestamibi and Tc-99m-tetrofosmin uptakes: a comparative study in sensitive U-87-MG and multidrug-resistant MRP1 human glioma cells. Cancer Biother Radiopharm 19:411–421
Andrews DW, Das R, Kim S, Zhang J, Curtis M (1997) Technetium-MIBI as a glioma imaging agent for the assessment of multi-drug resistance. Neurosurgery 40:1323–1332
Sasajima T, Shimada N, Naitoh Y et al (2007) (99m)Tc-MIBI imaging for prediction of therapeutic effects of second-generation MDR1 inhibitors in malignant brain tumors. Int J Cancer 121:2637–2645
Yokogami K, Kawano H, Moriyama T et al (1998) Application of SPET using technetium-99m sestamibi in brain tumours and comparison with expression of the MDR-1 gene: is it possible to predict the response to chemotherapy in patients with gliomas by means of 99mTc-sestamibi SPET? Eur J Nucl Med 25:401–409
Calatozzolo C, Gelati M, Ciusani E et al (2005) Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J Neurooncol 74:113–121
Declèves X, Fajac A, Lehmann-Che J et al (2002) Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines. Int J Cancer 98:173–80
Baldari S, Restifo Pecorella G, Cosentino S, Minutoli F (2002) Investigation of brain tumours with (99m)Tc-MIBI SPET. Q J Nucl Med 46:336–345
Fukumoto M (2004) Single-photon agents for tumor imaging: 201Tl, 99mTc-MIBI, and 99mTc-tetrofosmin. Ann Nucl Med 18:79–95
Alexiou GA, Tsiouris S, Goussia A et al (2008) Evaluation of glioma proliferation by 99mTc-Tetrofosmin. Neuro Oncol 10:104–105
Fotopoulos AD, Alexiou GA, Goussia A et al (2008) (99 m)Tc-Tetrofosmin brain SPECT in the assessment of meningiomas-correlation with histological grade and proliferation index. J Neurooncol 89:225–230
Alexiou GA, Vartholomatos G, Tsiouris S et al (2008) Evaluation of meningioma aggressiveness by (99m)Tc-Tetrofosmin SPECT. Clin Neurol Neurosurg 110:645–648
Alexiou GA, Fotopoulos AD, Kyritsis PA, AP PKS, Tsiouris S (2007) Evaluation of brain tumor recurrence by 99mTc-Tetrofosmin SPECT: a prospective pilot study. Ann Nucl Med 21:293–298
Alexiou GA, Bokharhii JA, Kyritsis AP, Polyzoidis KS, Fotopoulos AD (2006) Tc-99m Tetrofosmin SPECT for the differentiation of a cerebellar hemorrhage mimicking a brain metastasis from a renal cell carcinoma. J Neurooncol 78:207–208
Alexiou GA, Zigouris A, Pahaturidis D, Goussia A, Tsiouris S, Fotopoulos AD, Zagorianakou P, Voulgaris S (2007) Olfactory colloid cyst. Clin Neurol Neurosurg 109:902–904
Author information
Authors and Affiliations
Corresponding author
Additional information
Significance
99mTc-Tetrofosmin (TF) uptake is not influenced by glioma's multidrug resistance phenotype. Thus, 99mTc-TF is superior to 99mTc-Sestamibi and constitutes a suitable radiotracer for imaging gliomas.
Rights and permissions
About this article
Cite this article
Alexiou, G.A., Goussia, A., Kyritsis, A.P. et al. Influence of Glioma's Multidrug Resistance Phenotype on 99mTc-Tetrofosmin Uptake. Mol Imaging Biol 13, 348–351 (2011). https://doi.org/10.1007/s11307-010-0369-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11307-010-0369-y